MedTrace Logo

Study Comparing Two Different Tablet Formulations Of Bosutinib

NCT00934674 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2009-09-02

No results posted yet for this study

Summary

This study is comparing 2 formulations of bosutinib in healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

SKI-606 (Bosutinib)

Arm 1 - Commercial Tablet manufactured by Excella Arm 2 - Clinical Tablet manufactured by Wyeth Montreal

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Wyeth is now a wholly owned subsidiary of Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00934674 on ClinicalTrials.gov